Dr. Owen Garrick is President & Chief Operating Officer of Bridge Clinical Research.  Bridge CRO is the leading company focused on increasing the participation of ethnic minority investigators and patients in industry and institution sponsored clinical trials.

Dr. Garrick was formerly Director of Corporate Strategy and M&A at McKesson Corporation.  He led McKesson’s effort in vertical integration and was responsible for evaluating and managing new initiatives and business opportunities for the pharmaceutical division.  Prior to McKesson, Dr. Garrick was the Executive Director and Global Head of M&A Negotiations at Novartis Pharmaceuticals. Previously he spent four years at Goldman Sachs in New York, functioning as an investment advisor working with private healthcare companies as they sought to grow, raise capital, and perform initial public offerings. Dr. Garrick earned his MD from the Yale School of Medicine and his MBA from the Wharton School of Business. He holds an AB in Psychology from Princeton University. Dr. Garrick also serves on several boards and professional committees, including Sutter Health – East Bay Region, the New York Blood Center, Samuel Merritt University, and the American Medical Association Foundation where he was Board President. He was also recently confirmed to the HHS Secretary’s Advisory Committee on Human Research Protections.